Cite
HARVARD Citation
Mathur, R. et al. (2020). MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. Neuro-oncology. 22 (11), pp. 1580-1590. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Mathur, R. et al. (2020). MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. Neuro-oncology. 22 (11), pp. 1580-1590. [Online].